DH
GSK plc Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bepirovirsen | Chronic Hepatitis B (Functional Cure) | Phase III |
| Jemperli (dostarlimab) | 1L Endometrial Cancer | Phase III |
| Blenrep (belantamab mafodotin) | Relapsed/Refractory Multiple Myeloma | Phase III |
| Camlipixant (gefapixant) | Refractory Chronic Cough | Regulatory Review |
| GSK RSV Vaccine (Arexvy) | RSV Prevention (Older Adults) | Approved |
| Meningitis ABCWY Vaccine | Meningococcal Disease Prevention | Phase III |
| Cabenuva (CAB+RPV LA) | HIV-1 Maintenance Therapy | Approved |
| CAB LA (next-gen PrEP) | HIV Pre-Exposure Prophylaxis | Phase III |
Leadership Team at GSK plc
EW
Emma Walmsley
Chief Executive Officer
DT
Dr. Tony Wood
Chief Scientific Officer, President R&D
JB
Julie Brown
Chief Financial & Operating Officer
DW
Deborah Waterhouse
CEO, ViiV Healthcare; President, Global Health
DS
Dr. Sabine Luik
SVP, Global Medical & Clinical Affairs
DK
Dr. Kaivan Khavandi
SVP, Head of Respiratory/Immunology R&D
DR
David Redfern
Chairman of the Board